University Hospital Zurich, Clinical Pharmacology and Toxicology
Welcome,         Profile    Billing    Logout  
 0 Trials 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Trojan, Andreas
OGIPRO, NCT05234021: HER2-directed Biosimilar in Breast Cancer: Real World ePRO

Completed
N/A
52
Europe
OnkoZentrum Zürich AG, University of Zurich, Palleos Healthcare GmbH
HER2-positive Breast Cancer, Biosimilar, Patient Reported Outcome
06/23
06/23
PRO2, NCT05425550: Evaluation of the Medidux™ Digital Health Application in Patients with HER2-positive Breast Cancer During Chemotherapy in Combination with HER2-targeted Therapy or Antibody-drug Conjugate Therapy.

Recruiting
N/A
585
Europe
medidux™ app
Palleos Healthcare GmbH, Mobile Health AG
Breast Cancer
09/25
09/25

Download Options